X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Joint Bone Spine
; 88(5): 105208, 2021 10.
Article
in En
| MEDLINE
| ID: mdl-34102329
ABSTRACT
Hereditary hypophosphatemia with increased FGF23 levels are rare inherited metabolic diseases characterized by low serum phosphate because of impaired renal tubular phosphate reabsorption. The most common form is X-linked hypophosphatemia (XLH), secondary to a mutation in the PHEX gene. In children, XLH is often manifested by rickets, delayed development of gait, lower limb deformities, growth retardation, craniosynostosis, and spontaneous dental abscesses. In adults, patients present diffuse musculoskeletal pain (bone and joints), early osteoarthritis, entesopathies, pseudo-fractures, muscular weakness, and severe dental damage. Conventional medical management is based on the combined administration of oral phosphate supplementation with active vitamin D analogs. Treatment with the recently approved anti-FGF23 burosumab is an alternative, especially in severe forms. Burosumab restores phosphate reabsorption in the proximal tubule and stimulates the endogenous synthesis of calcitriol. In Europe, burosumab has been approved for the treatment of XLH with radiographic evidence of bone disease in pediatric patients from one year of age and in adults. This manuscript will discuss the specific management of burosumab in children and adolescents in daily practice.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hypophosphatemia
/
Familial Hypophosphatemic Rickets
Type of study:
Diagnostic_studies
Limits:
Adolescent
/
Adult
/
Child
/
Humans
Language:
En
Journal:
Joint Bone Spine
Journal subject:
REUMATOLOGIA
Year:
2021
Document type:
Article